KYTX Kyverna Therapeutics, Inc.
Legal ·
Kyverna Therapeutics is defending a Securities Act class action over its February 2024 IPO, which names the company, certain officers and directors, and the underwriters. A second amended complaint is under a motion to dismiss, with a hearing set for September 3, 2026. Two derivative suits filed in May 2025 were later consolidated.
Kyverna extended availability of $15.0 million in remaining Term A Loans to December 31, 2026, for a $187,500 upfront fee. Further changes to the facility apply only if the company draws the full $15.0 million.
Kyverna signed a loan facility of up to $150.0 million with Oxford Finance and drew $25.0 million at closing, secured by substantially all of its assets. The company says its runway still runs into 2027, the same guidance it gave before the loan.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $133.7 million | $112.5 million |
| Net income (loss) | -$161.3 million | -$127.5 million |
| Cash from operations | -$153.7 million | -$114.2 million |
| Cash and equivalents | $124.1 million | $96.6 million |
| Short-term investments | $155.2 million | $189.4 million |
Our latest story on this, dated Aug 11, 2026: "Kyverna faces IPO securities class action and consolidated derivative suit". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 11, 2026: "Kyverna faces IPO securities class action and consolidated derivative suit". The story links the filing or release it is based on. Read the story.
Kyverna Therapeutics, Inc. trades under the ticker KYTX on NASDAQ.
Kyverna Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Kyverna Therapeutics, Inc. is 1994702. Its filings are on SEC EDGAR.
61,843,444 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Kyverna Therapeutics, Inc. under United States.
Our directory classifies Kyverna Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Kyverna Therapeutics, Inc. is US5019761049.
aibio.space lists Kyverna Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Kyverna Therapeutics, Inc. reported a net loss of $161.3 million for the fiscal year ended Dec 31, 2025, and used $153.7 million of cash in operations, per its annual report to the SEC.
$133.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
$199.4 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Kyverna Therapeutics, dated Aug 11, 2026: "Kyverna faces IPO securities class action and consolidated derivative suit". Kyverna Therapeutics is defending a Securities Act class action over its February 2024 IPO, which names the company, certain officers and directors, and the underwriters. A second amended complaint is under a motion to dismiss, with a hearing set for September 3, 2026. Two derivative suits filed in May 2025 were later consolidated. Source.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio